SCHEMBL5873594

SCHEMBL5873594

CC(C(=O)O)c1c2cccccc-2c(C(C)C(=O)O)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.46
CYP2C19 P33261 3/20 0.41
CYP3A4 P08684 3/20 0.41
HPGD P15428 3/20 0.41
CYP2D6 P10635 2/20 0.41
DRD3 P35462 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
ADRA2C P18825 1/20 0.41
MAOA P21397 1/20 0.41
ADRA1A P35348 1/20 0.41
KCNH2 Q12809 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
LMNA P02545 4/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 2/20 0.41
PGR P06401 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000720 0.75 PTGS2 (0.44) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL3701250 0.74 PTGS2 (0.52) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL999079 0.73 PTGS2 (0.38) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL3840548 0.73 PTGS2 (0.47) PTGS2CYP2C19HPGDDRD3CYP1A2
SCHEMBL28195583 0.72 PTGS2 (0.40) PTGS2CYP2C19CYP3A4HPGDCYP2D6
Lactic Acid SCHEMBL14060787 0.71 TP53 (0.48) PTGS2MEN1KMT2ALMNATP53
Methylamine SCHEMBL31352744 0.70 PTGS2 (0.69) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL59839 0.69 PTGS2 (0.52) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL30338418 0.69 PTGS2 (0.52) PTGS2CYP2C19CYP3A4HPGDCYP2D6
SCHEMBL5215577 0.69 PTGS2 (0.52) PTGS2CYP2C19CYP3A4HPGDCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034174-B2 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GMBH (DE) 2006-04-25 US disclosed
EP-1318183-B1 Oligomers and Polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GMBH (DE) 2005-05-18 EP disclosed
US-20030122479-A1 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2003-07-03 US disclosed
EP-1318183-A1 Mono,- oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GmbH (DE) 2003-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030122479-A1 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials PARN, PARG, SLCO2A1 PTGS2 3215/4885CYP2C19 2378/4885CYP3A4 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.